David Crockford

David Crockford has more than 40 years of experience in the biotechnology and pharmaceutical industries with significant leadership in regulatory and clinical affairs, which included organizing, presenting, and leading discussions with FDA and other foreign regulatory agencies. He has established strategic plans, implemented, led the development, and obtained marketing approval of 18 drug products including one of the first human growth hormone preparations sold in the U.S. and the first “ready-to-inject” radiobiological, 17 in vitro diagnostic products, and an intraoperative medical device utilizing radiolabel monoclonal antibodies to detect and treat cancer.

David’s other accomplishments include implementation of sound regulatory and clinical strategies that led to the cost-effective and timely development of a number of innovative, investigational drugs, including various in the field of oncology. Recently, David worked closely with the National Cancer Institute on the development of a potentially enabling approach to improve responses to CAR T and antibody drug conjugates targeting CD22 with bryostatin in patients with leukemia and lymphoma. Earlier in his career he co-founded and presided over one of the first publicly-held companies in the field of genetic engineering, pioneering the development and commercial application of monoclonal antibodies for use in cancer diagnosis and treatment. David Crockford is the author of a number of articles and is the sole inventor/co-inventor on approximately twenty issued patents and patent applications.

David earned a BA in biology from Boston University and completed course studies and seminars at Princeton University, Wayne State’s C.S. Mott Center for Human Growth and Development, and UCLA Medical School.